31 results
Thumbnail

D2.167 - Effect of Metformin on allergen specific immunotherapy

Thumbnail

D2.169 - Association of Antenatal Corticosteroid Treatment with Risk of Allergic Diseases in Children

Thumbnail

D2.174 - Patient survey to determine the minimal clinically important difference for a combined symptom and medication score in grass AIT

Thumbnail

D2.179 - Evaluation of Sublingual Immunotherapy for Cat Allergy: Results from a Non-Interventional Study

Thumbnail

D2.168 - Systemic reactions to subcutaneous immunotherapy in children

Thumbnail

D2.170 - The placebo effect leads to significantly lower values regarding allergic symptoms and medication use in birch-pollen allergic patients during the birch pollen season

Thumbnail

D2.171 - The individual benefit of subcutaneous immunotherapy with mannan-conjugated birch pollen allergoids is already evident in the first season immediately after treatment

Thumbnail

D2.172 - Subcutaneous immunotherapy with a depigmented cat allergoid in patients with cat allergy is safe and results primarily in delayed local reactions

Thumbnail

D2.173 - Subcutaneous allergen-specific immunotherapies for inhalation allergens induce higher levels of therapy specific IgG4 antibodies than sublingual therapies: a retrospective data analysis

Thumbnail

D2.175 - TAPAS – non-inferiority of clinical effectiveness in children compared to adults: interim results of a long-term NIS

Thumbnail

D2.176 - Improved quality of life after PQ Grass in comparison to SLIT products in grass allergic patients

Thumbnail

D2.177 - The Efficacy of Sublingual Immunotherapy in Mild versus Moderate Atopic Dermatitis Among Children with House Dust Mite Allergic Rhinitis

Thumbnail

D2.178 - Allergen-specific IgE/IgG4 ratio as biomarker of allergen immunotherapy efficacy in house dust mite-sensitized allergic rhinitis

Thumbnail

D2.180 - Immunological evaluation of cat allergic individuals living with or without a cat

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria